KEGG   PATHWAY: mpah05224
Entry
mpah05224                   Pathway                                
Name
Breast cancer - Mus pahari (shrew mouse)
Description
Breast cancer is the leading cause of cancer death among women worldwide. The vast majority of breast cancers are carcinomas that originate from cells lining the milk-forming ducts of the mammary gland. The molecular subtypes of breast cancer, which are based on the presence or absence of hormone receptors (estrogen and progesterone subtypes) and human epidermal growth factor receptor-2 (HER2), include: hormone receptor positive and HER2 negative (luminal A subtype), hormone receptor positive and HER2 positive (luminal B subtype), hormone receptor negative and HER2 positive (HER2 positive), and hormone receptor negative and HER2 negative (basal-like or triple-negative breast cancers (TNBCs)). Hormone receptor positive breast cancers are largely driven by the estrogen/ER pathway. In HER2 positive breast tumours, HER2 activates the PI3K/AKT and the RAS/RAF/MAPK pathways, and stimulate cell growth, survival and differentiation. In patients suffering from TNBC, the deregulation of various signalling pathways (Notch and Wnt/beta-catenin), EGFR protein have been confirmed. In the case of breast cancer only 8% of all cancers are hereditary, a phenomenon linked to genetic changes in BRCA1 or BRCA2. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers.
Class
Human Diseases; Cancer: specific types
Pathway map
mpah05224  Breast cancer
mpah05224

Organism
Mus pahari (shrew mouse) [GN:mpah]
Gene
110337903  Esr1; estrogen receptor isoform X1 [KO:K08550]
110324053  Esr2; estrogen receptor beta [KO:K08551]
110323985  Ncoa1; nuclear receptor coactivator 1 isoform X1 [KO:K09101] [EC:2.3.1.48]
110318560  Ncoa3; nuclear receptor coactivator 3 [KO:K11256] [EC:2.3.1.48]
110324365  Fos; proto-oncogene c-Fos isoform X1 [KO:K04379]
110323252  Jun; transcription factor AP-1 [KO:K04448]
110334488  Sp1; transcription factor Sp1 isoform X1 [KO:K04684]
110322378  Ccnd1; G1/S-specific cyclin-D1 [KO:K04503]
110334656  Myc; myc proto-oncogene protein [KO:K04377]
110327945  Pgr; progesterone receptor isoform X1 [KO:K08556]
110335204  Wnt1; proto-oncogene Wnt-1 [KO:K03209]
110323343  Wnt4; protein Wnt-4 isoform X1 [KO:K00408]
110325778  Tnfsf11; tumor necrosis factor ligand superfamily member 11 isoform X1 [KO:K05473]
110331339  Erbb2; receptor tyrosine-protein kinase erbB-2 [KO:K05083] [EC:2.7.10.1]
110333309  Fgf1; fibroblast growth factor 1 isoform X1 [KO:K18496]
110320512  Fgf2; fibroblast growth factor 2 isoform X1 [KO:K18497]
110314005  Fgf16; fibroblast growth factor 16 [KO:K04358]
110325648  Fgf17; fibroblast growth factor 17 isoform X1 [KO:K04358]
110318603  Fgf7; fibroblast growth factor 7 [KO:K04358]
110326486  Fgf8; fibroblast growth factor 8 isoform X1 [KO:K04358]
110325518  Fgf9; fibroblast growth factor 9 [KO:K04358]
110337766  Fgf3; fibroblast growth factor 3 [KO:K04358]
110332000  Fgf18; fibroblast growth factor 18 [KO:K04358]
110336807  Fgf20; fibroblast growth factor 20 [KO:K04358]
110317154  Fgf6; fibroblast growth factor 6 [KO:K04358]
110327081  Fgf22; fibroblast growth factor 22 isoform X1 [KO:K04358]
110330786  Fgf5; fibroblast growth factor 5 isoform X1 [KO:K04358]
110336606  Fgf4; fibroblast growth factor 4 [KO:K04358]
110329060  Fgf10; fibroblast growth factor 10 [KO:K04358]
110334904  Fgf19; fibroblast growth factor 19 [KO:K22603]
110338839  Fgf21; fibroblast growth factor 21 [KO:K22429]
110317286  Fgf23; fibroblast growth factor 23 [KO:K22428]
110336809  Fgfr1; fibroblast growth factor receptor 1 [KO:K04362] [EC:2.7.10.1]
110326668  Igf1; insulin-like growth factor I isoform X1 [KO:K05459]
110324292  Igf1r; insulin-like growth factor 1 receptor isoform X1 [KO:K05087] [EC:2.7.10.1]
110320006  Egf; pro-epidermal growth factor isoform X1 [KO:K04357]
110330480  Egfr; epidermal growth factor receptor isoform X1 [KO:K04361] [EC:2.7.10.1]
110330230  Kit; mast/stem cell growth factor receptor Kit isoform X1 [KO:K05091] [EC:2.7.10.1]
110320247  Shc1; SHC-transforming protein 1 isoform X1 [KO:K06279]
110326457  Shc2; SHC-transforming protein 2 [KO:K17447]
110333751  Shc3; SHC-transforming protein 3 isoform X1 [KO:K17448]
110318126  Shc4; SHC-transforming protein 4 [KO:K17449]
110331195  Grb2; growth factor receptor-bound protein 2 isoform X1 [KO:K04364]
110335780  Sos1; son of sevenless homolog 1 [KO:K03099]
110324314  Sos2; son of sevenless homolog 2 isoform X1 [KO:K03099]
110318967  GTPase HRas-like isoform X1 [KO:K02833]
110319567  Hras; GTPase HRas [KO:K02833]
110338480  GTPase HRas-like [KO:K02833]
110333346  GTPase HRas-like [KO:K02833]
110316221  Kras; GTPase KRas isoform X1 [KO:K07827]
110320340  Nras; GTPase NRas [KO:K07828]
110314283  Araf; serine/threonine-protein kinase A-Raf [KO:K08845] [EC:2.7.11.1]
110316269  Braf; serine/threonine-protein kinase B-raf [KO:K04365] [EC:2.7.11.1]
110314893  Raf1; RAF proto-oncogene serine/threonine-protein kinase isoform X1 [KO:K04366] [EC:2.7.11.1]
110327244  Map2k1; dual specificity mitogen-activated protein kinase kinase 1 [KO:K04368] [EC:2.7.12.2]
110326321  Map2k2; dual specificity mitogen-activated protein kinase kinase 2 isoform X1 [KO:K04369] [EC:2.7.12.2]
110329343  Mapk1; mitogen-activated protein kinase 1 isoform X1 [KO:K04371] [EC:2.7.11.24]
110320020  Mapk3; mitogen-activated protein kinase 3 isoform X1 [KO:K04371] [EC:2.7.11.24]
110323448  Pik3cd; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
110319750  Pik3ca; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
110327251  Pik3cb; phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform isoform X1 [KO:K00922] [EC:2.7.1.153]
110328811  Pik3r1; phosphatidylinositol 3-kinase regulatory subunit alpha isoform X1 [KO:K02649]
110336420  Pik3r2; phosphatidylinositol 3-kinase regulatory subunit beta [KO:K02649]
110322865  Pik3r3; phosphatidylinositol 3-kinase regulatory subunit gamma isoform X1 [KO:K02649]
110312812  Pten; phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN [KO:K01110] [EC:3.1.3.16 3.1.3.48 3.1.3.67]
110317258  Akt2; RAC-beta serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
110324386  Akt1; RAC-alpha serine/threonine-protein kinase isoform X1 [KO:K04456] [EC:2.7.11.1]
110322284  Akt3; RAC-gamma serine/threonine-protein kinase [KO:K04456] [EC:2.7.11.1]
110323363  Mtor; serine/threonine-protein kinase mTOR [KO:K07203] [EC:2.7.11.1]
110315992  Rps6kb2; ribosomal protein S6 kinase beta-2 [KO:K04688] [EC:2.7.11.1]
110331448  Rps6kb1; ribosomal protein S6 kinase beta-1 isoform X1 [KO:K04688] [EC:2.7.11.1]
110317574  Jag1; protein jagged-1 [KO:K06052]
110324260  Jag2; protein jagged-2 isoform X1 [KO:K21635]
110338215  Dll1; delta-like protein 1 isoform X1 [KO:K06051]
110326973  Dll3; delta-like protein 3 isoform X1 [KO:K06051]
110318243  Dll4; delta-like protein 4 isoform X1 [KO:K06051]
110318758  Notch1; neurogenic locus notch homolog protein 1 [KO:K02599]
110319730  Notch2; neurogenic locus notch homolog protein 2 [KO:K20994]
110335972  Notch3; LOW QUALITY PROTEIN: neurogenic locus notch homolog protein 3 [KO:K20995]
110335523  Notch4; neurogenic locus notch homolog protein 4 [KO:K20996]
110329664  Hes1; transcription factor HES-1 [KO:K06054]
110323377  Hes5; transcription factor HES-5 [KO:K06055]
110320084  Hey1; hairy/enhancer-of-split related with YRPW motif protein 1 [KO:K09091]
110323441  Heyl; hairy/enhancer-of-split related with YRPW motif-like protein [KO:K09091]
110338033  Hey2; hairy/enhancer-of-split related with YRPW motif protein 2 [KO:K09091]
110331550  Flt4; vascular endothelial growth factor receptor 3 [KO:K05097] [EC:2.7.10.1]
110338236  Cdkn1a; cyclin-dependent kinase inhibitor 1 [KO:K06625]
110317480  Nfkb2; nuclear factor NF-kappa-B p100 subunit isoform X1 [KO:K04469]
110316416  Wnt2; protein Wnt-2 [KO:K00182]
110320339  Wnt2b; protein Wnt-2b [KO:K00182]
110331952  Wnt3; proto-oncogene Wnt-3 [KO:K00312]
110331285  Wnt3a; protein Wnt-3a [KO:K00312]
110316538  Wnt5b; protein Wnt-5b [KO:K00444]
110325571  Wnt5a; protein Wnt-5a isoform X1 [KO:K00444]
110321884  Wnt6; protein Wnt-6 [KO:K00445]
110316305  Wnt7a; protein Wnt-7a [KO:K00572]
110335001  Wnt7b; protein Wnt-7b isoform X1 [KO:K00572]
110330357  Wnt8b; protein Wnt-8b [KO:K00714]
110333515  Wnt8a; protein Wnt-8a [KO:K00714]
110331284  Wnt9a; protein Wnt-9a isoform X1 [KO:K01064]
110332442  Wnt9b; protein Wnt-9b [KO:K01064]
110335137  Wnt10b; protein Wnt-10b isoform X1 [KO:K01357]
110322230  Wnt10a; protein Wnt-10a [KO:K01357]
110325401  Wnt11; protein Wnt-11 isoform X1 [KO:K01384]
110317136  Wnt16; protein Wnt-16 [KO:K01558]
110316646  Fzd1; frizzled-1 [KO:K02432]
110321753  Fzd7; frizzled-7 [KO:K02432]
110331922  Fzd2; frizzled-2 [KO:K02235]
110325524  Fzd3; frizzled-3 [KO:K02329]
110325899  Fzd4; frizzled-4 [KO:K02354]
110321741  Fzd5; frizzled-5 [KO:K02375]
110333155  Fzd8; frizzled-8 [KO:K02375]
110334890  Fzd6; frizzled-6 [KO:K02376]
110339184  Fzd10; frizzled-10 [KO:K02842]
110312856  Fzd9; frizzled-9 [KO:K02842]
110338873  Lrp5; low-density lipoprotein receptor-related protein 5 [KO:K03068]
110314261  Lrp6; low-density lipoprotein receptor-related protein 6 isoform X1 [KO:K03068]
110329595  Dvl3; segment polarity protein dishevelled homolog DVL-3 isoform X1 [KO:K02353]
110323116  Dvl1; segment polarity protein dishevelled homolog DVL-1 isoform X1 [KO:K02353]
110331183  Dvl2; segment polarity protein dishevelled homolog DVL-2 isoform X1 [KO:K02353]
110324178  proto-oncogene FRAT1-like [KO:K03069]
110329160  Frat1; proto-oncogene FRAT1 [KO:K03069]
110331957  Frat2; GSK-3-binding protein FRAT2 [KO:K03096]
110329614  Gsk3b; glycogen synthase kinase-3 beta isoform X1 [KO:K03083] [EC:2.7.11.26]
110338127  Axin1; axin-1 isoform X1 [KO:K02157]
110331423  Axin2; axin-2 [KO:K04385]
110333195  Apc; adenomatous polyposis coli protein isoform X1 [KO:K02085]
110326173  Apc2; adenomatous polyposis coli protein 2 isoform X1 [KO:K02085]
110328516  Ctnnb1; catenin beta-1 isoform X1 [KO:K02105]
110333354  Csnk1a1; casein kinase I isoform X1 [KO:K08957] [EC:2.7.11.1]
110332085  Tcf7; transcription factor 7 isoform X1 [KO:K02620]
110315696  Tcf7l1; transcription factor 7-like 1 isoform X1 [KO:K04490]
110313411  Tcf7l2; transcription factor 7-like 2 isoform X1 [KO:K04491]
110319903  Lef1; lymphoid enhancer-binding factor 1 isoform X1 [KO:K04492]
110331731  Tp53; cellular tumor antigen p53 isoform X1 [KO:K04451]
110316550  Gadd45a; growth arrest and DNA damage-inducible protein GADD45 alpha isoform X1 [KO:K04402]
110326839  Gadd45b; growth arrest and DNA damage-inducible protein GADD45 beta [KO:K04402]
110333844  Gadd45g; growth arrest and DNA damage-inducible protein GADD45 gamma [KO:K04402]
110320030  Bax; apoptosis regulator BAX isoform X1 [KO:K02159]
110338169  Bak1; bcl-2 homologous antagonist/killer isoform X1 [KO:K14021]
110319597  Ddb2; DNA damage-binding protein 2 isoform X1 [KO:K10140]
110329143  Polk; DNA polymerase kappa isoform X1 [KO:K03511] [EC:2.7.7.7]
110326196  Cdk4; cyclin-dependent kinase 4 [KO:K02089] [EC:2.7.11.22]
110316496  Cdk6; cyclin-dependent kinase 6 [KO:K02091] [EC:2.7.11.22]
110325233  Rb1; retinoblastoma-associated protein [KO:K06618]
110318578  E2f1; transcription factor E2F1 [KO:K17454]
110323461  E2f2; transcription factor E2F2 [KO:K09389]
110333784  E2f3; transcription factor E2F3 isoform X1 [KO:K06620]
110331180  Brca1; breast cancer type 1 susceptibility protein isoform X1 [KO:K10605] [EC:2.3.2.27]
110312957  Brca2; breast cancer type 2 susceptibility protein [KO:K08775]
Compound
C00410  Progesterone
C00951  Estradiol-17beta
C05981  Phosphatidylinositol-3,4,5-trisphosphate
Reference
  Authors
Zhang MH, Man HT, Zhao XD, Dong N, Ma SL
  Title
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review).
  Journal
Biomed Rep 2:41-52 (2014)
DOI:10.3892/br.2013.187
Reference
  Authors
Dai X, Xiang L, Li T, Bai Z
  Title
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
  Journal
J Cancer 7:1281-94 (2016)
DOI:10.7150/jca.13141
Reference
  Authors
Schnitt SJ
  Title
Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy.
  Journal
Mod Pathol 23 Suppl 2:S60-4 (2010)
DOI:10.1038/modpathol.2010.33
Reference
  Authors
  Title
Comprehensive molecular portraits of human breast tumours.
  Journal
Nature 490:61-70 (2012)
DOI:10.1038/nature11412
Reference
  Authors
Eroles P, Bosch A, Perez-Fidalgo JA, Lluch A
  Title
Molecular biology in breast cancer: intrinsic subtypes and signaling pathways.
  Journal
Cancer Treat Rev 38:698-707 (2012)
DOI:10.1016/j.ctrv.2011.11.005
Reference
  Authors
Karamouzis MV, Papavassiliou KA, Adamopoulos C, Papavassiliou AG.
  Title
Targeting androgen/estrogen receptors crosstalk in cancer
  Journal
Trends Cancer 2:35-48 (2016)
DOI:10.1016/j.trecan.2015.12.001
Reference
  Authors
Sharp A, Harper-Wynne C.
  Title
Treatment of advanced breast cancer (ABC): the expanding landscape of targeted therapies
  Journal
J Cancer Biol Res 2:1036 (2014)
Reference
  Authors
Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, Sarkar S
  Title
Genetic and epigenetic aspects of breast cancer progression and therapy.
  Journal
Anticancer Res 34:1071-7 (2014)
Reference
  Authors
Mohamed A, Krajewski K, Cakar B, Ma CX
  Title
Targeted therapy for breast cancer.
  Journal
Am J Pathol 183:1096-112 (2013)
DOI:10.1016/j.ajpath.2013.07.005
Reference
  Authors
Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, Van Tine BA, Hoog J, Goiffon RJ, Goldstein TC, Ng S, Lin L, Crowder R, Snider J, Ballman K, Weber J, Chen K, Koboldt DC, Kandoth C, Schierding WS, McMichael JF, Miller CA, Lu C, Harris CC, McLellan MD, Wendl MC, DeSchryver K, Allred DC, Esserman L, Unzeitig G, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Leitch M, Hunt K, Olson J, Tao Y, Maher CA, Fulton LL, Fulton RS, Harrison M, Oberkfell B, Du F, Demeter R, Vickery TL, Elhammali A, Piwnica-Worms H, McDonald S, Watson M, Dooling DJ, Ota D, Chang LW, Bose R, Ley TJ, Piwnica-Worms D, Stuart JM, Wilson RK, Mardis ER
  Title
Whole-genome analysis informs breast cancer response to aromatase inhibition.
  Journal
Nature 486:353-60 (2012)
DOI:10.1038/nature11143
Reference
  Authors
Ma CX, Reinert T, Chmielewska I, Ellis MJ
  Title
Mechanisms of aromatase inhibitor resistance.
  Journal
Nat Rev Cancer 15:261-75 (2015)
DOI:10.1038/nrc3920
Reference
  Authors
Butt AJ, McNeil CM, Musgrove EA, Sutherland RL
  Title
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E.
  Journal
Endocr Relat Cancer 12 Suppl 1:S47-59 (2005)
DOI:10.1677/erc.1.00993
Reference
  Authors
Dasgupta S, Lonard DM, O'Malley BW
  Title
Nuclear receptor coactivators: master regulators of human health and disease.
  Journal
Annu Rev Med 65:279-92 (2014)
DOI:10.1146/annurev-med-051812-145316
Reference
  Authors
Brisken C
  Title
Progesterone signalling in breast cancer: a neglected hormone coming into the limelight.
  Journal
Nat Rev Cancer 13:385-96 (2013)
DOI:10.1038/nrc3518
Reference
  Authors
Scarpin KM, Graham JD, Mote PA, Clarke CL
  Title
Progesterone action in human tissues: regulation by progesterone receptor (PR) isoform expression, nuclear positioning and coregulator expression.
  Journal
Nucl Recept Signal 7:e009 (2009)
DOI:10.1621/nrs.07009
Reference
  Authors
Knutson TP, Lange CA
  Title
Tracking progesterone receptor-mediated actions in breast cancer.
  Journal
Pharmacol Ther 142:114-25 (2014)
DOI:10.1016/j.pharmthera.2013.11.010
Reference
  Authors
Dittrich A, Gautrey H, Browell D, Tyson-Capper A
  Title
The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
  Journal
J Mammary Gland Biol Neoplasia 19:253-70 (2014)
DOI:10.1007/s10911-014-9329-5
Reference
  Authors
Higgins MJ, Baselga J
  Title
Targeted therapies for breast cancer.
  Journal
J Clin Invest 121:3797-803 (2011)
DOI:10.1172/JCI57152
Reference
  Authors
Mukohara T
  Title
PI3K mutations in breast cancer: prognostic and therapeutic implications.
  Journal
Breast Cancer (Dove Med Press) 7:111-23 (2015)
DOI:10.2147/BCTT.S60696
Reference
  Authors
Schneider BP, Winer EP, Foulkes WD, Garber J, Perou CM, Richardson A, Sledge GW, Carey LA
  Title
Triple-negative breast cancer: risk factors to potential targets.
  Journal
Clin Cancer Res 14:8010-8 (2008)
DOI:10.1158/1078-0432.CCR-08-1208
Reference
  Authors
King TD, Suto MJ, Li Y
  Title
The Wnt/beta-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer.
  Journal
J Cell Biochem 113:13-8 (2012)
DOI:10.1002/jcb.23350
Reference
  Authors
Brown AM
  Title
Wnt signaling in breast cancer: have we come full circle?
  Journal
Breast Cancer Res 3:351-5 (2001)
DOI:10.1186/bcr321
Reference
  Authors
Geyer FC, Lacroix-Triki M, Savage K, Arnedos M, Lambros MB, MacKay A, Natrajan R, Reis-Filho JS
  Title
beta-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation.
  Journal
Mod Pathol 24:209-31 (2011)
DOI:10.1038/modpathol.2010.205
Reference
  Authors
Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS
  Title
Notch signaling pathway as a therapeutic target in breast cancer.
  Journal
Mol Cancer Ther 10:9-15 (2011)
DOI:10.1158/1535-7163.MCT-10-0677
Reference
  Authors
Rangel MC, Bertolette D, Castro NP, Klauzinska M, Cuttitta F, Salomon DS
  Title
Developmental signaling pathways regulating mammary stem cells and contributing to the etiology of triple-negative breast cancer.
  Journal
Breast Cancer Res Treat 156:211-26 (2016)
DOI:10.1007/s10549-016-3746-7
Reference
  Authors
Jamdade VS, Sethi N, Mundhe NA, Kumar P, Lahkar M, Sinha N
  Title
Therapeutic targets of triple-negative breast cancer: a review.
  Journal
Br J Pharmacol 172:4228-37 (2015)
DOI:10.1111/bph.13211
Reference
  Authors
Karamboulas C, Ailles L
  Title
Developmental signaling pathways in cancer stem cells of solid tumors.
  Journal
Biochim Biophys Acta 1830:2481-95 (2013)
DOI:10.1016/j.bbagen.2012.11.008
Reference
  Authors
Ignatiadis M, Sotiriou C
  Title
Luminal breast cancer: from biology to treatment.
  Journal
Nat Rev Clin Oncol 10:494-506 (2013)
DOI:10.1038/nrclinonc.2013.124
Reference
  Authors
Shin SJ, Gong G, Lee HJ, Kang J, Bae YK, Lee A, Cho EY, Lee JS, Suh KS, Lee DW, Jung WH
  Title
Positive expression of insulin-like growth factor-1 receptor is associated with a positive hormone receptor status and a favorable prognosis in breast cancer.
  Journal
J Breast Cancer 17:113-20 (2014)
DOI:10.4048/jbc.2014.17.2.113
Reference
  Authors
Gasco M, Shami S, Crook T
  Title
The p53 pathway in breast cancer.
  Journal
Breast Cancer Res 4:70-6 (2002)
DOI:10.1186/bcr426
Reference
  Authors
Narod SA, Foulkes WD
  Title
BRCA1 and BRCA2: 1994 and beyond.
  Journal
Nat Rev Cancer 4:665-76 (2004)
DOI:10.1038/nrc1431
Related
pathway
mpah03440  Homologous recombination
mpah04010  MAPK signaling pathway
mpah04110  Cell cycle
mpah04115  p53 signaling pathway
mpah04151  PI3K-Akt signaling pathway
mpah04310  Wnt signaling pathway
mpah04330  Notch signaling pathway
mpah04915  Estrogen signaling pathway
KO pathway
ko05224   
LinkDB

DBGET integrated database retrieval system